BACKGROUND: Few patients with migraine syndrome receive treatment with preventive medication regimens, and some of these patients fail to gain adequate migraine relief. Botulinum toxin has been suggested to be effective in the treatment of migraine for a select population. An integrated health system created a medical policy and a supporting preauthorization form that permits coverage of botulinum toxin for the off-label treatment of migraine for patients who (1) fail at least 3 drug classes for acute treatment, (2) fail at least 4 different preventive medication classes, and (3) receive consultation from a neurologist.
METHODS:
The study was a retrospective analysis of administrative claims data from a 500,000-member integrated health system for the time period A survey was sent to the identified patients (N = 54) to assess 6 QOL measures associated with the use of botulinum toxin. Self-reported symptomatic improvement was assessed using a 5-point Likert scale for 6 questions regarding headache severity, headache frequency, use of rescue medications, productivity/absenteeism, recreational activities, and life enjoyment. For the subset of patients (n = 32) who maintained health plan eligibility from 18 months before through 18 months after the first botulinum toxin therapy claim (index date), medical and pharmacy claims data were used to assess the utilization and cost of specific medications and overall pharmacy and medical costs for the 18-month pre-index and post-index periods. Cost was defined as allowed charge, which is the sum of plan cost and member cost.
RESULTS: Of 54 surveys sent to all patients identified as having used botulinum toxin for the treatment of migraine from January 1, 2003, to October 31, 2006, 34 surveys were returned (63%). Almost 3 of 4 respondents (73%) reported moderate or better improvement in overall migraine or headache QOL measures, and 27% reported little or no improvement. For the 32 patients with continuous eligibility for the total observation period of 36 months, the average migraine-related pharmacy utilization, excluding botulinum toxin, increased by 50.5%, from 1.84 claims per patient per month (PPPM) in the 18-month pre-index period to 2.77 claims PPPM in the 18-month post-index period (P = 0.011) and by 59.5% by mean days supply (42.58 days to 67.93, P = 0.008). Total migraine-related pharmacy cost increased by 80.9%, from $142.08 PPPM to $256.97 PPPM (P = 0.013). Acute-treatment migraine-related pharmacy utilization increased from 1.23 claims PPPM to 1.92 claims PPPM (P = 0.004). There was no significant change in either the number of claims for migraine prophylaxis medications (0.61 PPPM to 0.85 PPPM, P = 0.121) or the use of hospital emergency room services related to migraine or headache (0.07 PPPM vs. 0.10 PPPM, P = 0.449). The mean migraine-related and nonmigraine-related (i.e., all-cause) combined medical/hospital and pharmacy expense, including botulinum toxin, increased by 111.3%, from $651.13 PPPM in the pre-index period to $1,376.05 PPPM in the post-index period (P < 0.001).
• Previous research among 8,488 triptan users found mean migraine-related pharmacy cost of $871 per patient per year (PPPY), 88.1% of total mean migraine-related cost of $989 PPPY in 1998-2001 dollars. However, continuous triptan users had mean migraine-related pharmacy costs ($1,505 PPPY) that were nearly 3 times the mean costs for new triptan users ($506 PPPY). • Approximately 3.4% (n = 286) of all 8,488 triptan users, or 25.4% of high-triptan users (n = 1,124), received drug prophylaxis. Drug prophylaxis in high-triptan users (moderate-to-severe migraine patients, defined as at least 18 triptan equivalents in 6 monthsthe quantity to treat more than 2 migraine episodes per month) was associated with a decrease of $560 PPPY (95% confidence interval = $514-$607) in 1998-2001 dollars.
• Only 28% of migraine sufferers are very satisfied with their usual treatment, and half of migraine patients stop seeking care for their headaches, partly because they are dissatisfied with therapy.
• Botulinum toxin has been used off-label by neurologists for patients refractory to more conventional treatment.
• Real-world payer data showing utilization of services and patient-reported QOL data are lacking.
• Payers often require some type of preauthorization prior to payment for botulinum toxin because of the potential for cosmetic and off-label uses. M igraine headaches are a common condition affecting 6% of men and 15% to 17% of women in the United States.
What is already known about this subject R E S E A R C H
1 Migraine is one of the most common reasons for patients to seek care with providers, accounting for 10 million office visits annually, but only 3% to 5% of patients receive preventive therapy. A recent analysis by Corianne et al. found that of 55% of patients with 2 or more migraine attacks per month who wanted preventive therapy, only 8% actually used this treatment.
2
In a different analysis of 8,488 triptan users, Etemad et al. found that new triptan users used fewer triptan unit equivalents than patients continually using triptans (medians 11 vs. 30, respectively, P < 0.05). 3 Etemad et al. also found that 3.4% (n = 286) of triptan users, or 25.4% of patients using 18 or more triptan equivalents in a 6-month period, received preventive medications; the average treatment effect of preventive medications was a decrease of $560 per patient per year (PPPY) (95% confidence interval [CI] = $514-$607 in 2001 dollars).
Despite consultation with neurologists and multiple trials on preventive therapy, such as certain anti-epileptics, calcium channel antagonists, beta-blockers, and tricyclic antidepressants, some patients fail to find symptomatic relief. Only 28% of migraine sufferers are very satisfied with their usual treatment, and half of migraine patients stop seeking care for their headaches, partly because they are dissatisfied with therapy. 4 Botulinum toxin has been suggested as an alternative treatment in some treatment-resistant migraine patients, but a literature review in 2008 concluded that it was probably not more effective than placebo in migraine patients.
5
Botulinum toxin has not been approved by the U.S. Food and Drug Administration (FDA) for the prevention or treatment of migraines or headaches. However, case studies, as well as placebo injection and oral comparison studies, have been conducted and published around the use of botulinum toxin in migraine and headache. These studies have demonstrated mixed efficacy results for reduction in the frequency of migraines and severity of migraine symptoms. A literature review by Naumann et al. (2008) concluded that the use of botulinum toxin in the treatment of episodic migraine and tension-type headache is probably not effective, and there is insufficient evidence to conclude effectiveness in chronic daily headache. Schulte-Mattler and Leinisch found, in their review of the literature published in late 2007, that randomized, doubleblind, placebo-controlled trials had been published for a total of 1,117 patients with chronic daily headache, 553 patients with tension-type headache, and 1,495 with chronic migraine. They concluded that botulinum toxin was comparable to placebo injection in efficacy and similar to the magnitude of effect from oral drug therapy. 6 Cady and Schreiber, in a 3-month placebocontrolled trial with crossover to 3 months of open label, found that, compared with baseline, patients treated with botulinum toxin showed improvements in measures of headache frequency. 7 For the measures of headache impact and treatment satisfaction, patients treated with botulinum toxin showed improvement compared with baseline and placebo. For the measures of headache frequency and severity, patients treated with botulinum toxin did not differ from placebo-treated patients.
Many payers restrict the coverage of botulinum toxin to uses approved by the FDA and, in some cases, to off-label use in certain circumstances when effective alternative therapies have failed. Because of the lack of symptom relief and quality-of-life (QOL) burden for select patients affected by migraine and headaches who failed conservative therapies, an integrated health system of approximately 500,000 members evaluated the coverage of botulinum toxin. Early in 2003, the integrated health system created a medical and preauthorization policy that permits coverage of botulinum toxin for the off-label treatment of migraine for patients who (1) fail at least 3 different acute treatment therapy classes, (2) fail at least 4 different preventive medication classes, and (3) receive consultation from a neurologist.
With 4 years of coverage data, querying patients about their satisfaction with botulinum toxin treatment and analyzing treatment utilization patterns became feasible. The objective of the analysis was multifold. First, understanding if botulinum toxin treatment positively affects humanistic measures would help inform coverage decisions. Second, the analysis of migrainerelated medication use and migraine-related emergency room (ER) visits before and after the use of botulinum toxin was needed for an objective understanding of the effect of botulinum toxin on migraine and headaches.
■■ Methods
Patients eligible to participate in the QOL survey were identified based on administrative claims data ( Figure 1 Surveys were sent to 54 patients with an explanation of the study approved by the Intermountain Healthcare Office of Research Institutional Review Board, a preaddressed and stamped envelope to return, and a $5.00 bill. The survey included 6 QOL measures for self-reported assessment using a 5-point Likert scale (no improvement, a little improvement, moderately improved, quite a bit improved, or extremely improved) rating headache severity, headache frequency, use of rescue medications, productivity/absenteeism, recreational activities, and life enjoyment. A composite QOL score was calculated by summing the 6 measures for each of the Likert scale categories.
In order to assess the use and cost of migraine-related medications and overall medical and pharmacy services before and after the initiation of botulinum toxin therapy, administrative claims were analyzed. Medical and pharmacy claims from January 1, 2003, through October 31, 2007, were used to assess utilization and cost for 18 months before and after initial botulinum toxin therapy for the group of patients who received a QOL survey. Of 54 patients, 32 maintained eligibility for utilization and cost analysis. Eligibility required health plan membership for at least 18 months before and 18 months after the index date. The index date was defined as the date of service of the first botulinum toxin claim. Cost was defined as allowed charge, which is the sum of plan cost and member cost. Migraine-related ER costs and utilization were identified by administrative claims of ER use (place of service code = 23 [ER] and revenue codes = 450, 451, 459, and 981 [indicating a bill for ER services]) with a primary diagnosis of migraine or headache (ICD-9-CM codes of 346.xx, 307.81, or 784.0). Migraine-related pharmacy claims were identified using Medi-Span Generic Product Identifier codes identified in Table 1 .
For the 18-month pre-index and post-index periods, mean per patient per month (PPPM) all-cause pharmacy and medical costs and utilization (number of claims) and migraine-related pharmacy costs and utilization (number of claims, number of dispensed days supply) were calculated. For the same 36-month period, migraine-related ER visits were calculated per patient per quarter (PPPQ). Changes in the mean values from the pre-index to post-index period were assessed for statistical significance using the paired t-test. The significance level was set at 0.05. Analyses were performed by an internal data analyst using Analysis ToolPak 2003. 
■■ Results
Of 54 QOL assessment surveys sent to all patients identified as using botulinum toxin for migraine from January 1, 2003, through October 31, 2006, 34 surveys were returned (63%). The composite score analysis indicated that nearly 3 of 4 respondents (73%) reported moderate or better improvement in overall migraine or headache QOL measures, and 27% reported little or no improvement. Improvement scores for individual questions, as well as composite scores, are shown in Table 2 and Figures 2,  3 , and 4. Of 54 patients, 32 were eligible for financial and utilization analyses for the 18-month pre-index and post-index periods. The majority of patients were female (84%), and the mean age at the index, first botulinum toxin therapy date, was 40.44 years with an SD of 11.02 (data not shown). Migraine-related pharmacy cost and utilization results before and after botulinum toxin therapy are displayed in Table 3 . Total migraine-related pharmacy cost increased by 80.9%, from $142.08 PPPM to $256.97 PPPM (P = 0.013). Total migraine-related number of prescriptions and days supply of therapy also increased, by 50.5% from 1.84 prescriptions PPPM to 2.77 prescriptions PPPM (P = 0.011) and by 59.5% from 42.58 days of therapy PPPM to 67.93 days of therapy PPPM (P = 0.008), respectively.
Cost for acute-treatment and prophylactic-treatment migrainerelated pharmacy claims both increased significantly, from $73.51 PPPM to $133.39 PPPM (P = 0.042) and from $68.56 PPPM to $123.58 PPPM (P = 0.040), respectively. Acute-treatment migraine-related pharmacy utilization increased from 1.23 claims PPPM to 1.92 claims PPPM (P = 0.004) and 22.27 days of therapy PPPM to 37.69 days of therapy PPPM (P = 0.003), respectively. However, pharmacy utilization of prophylactic treatment for migraine did not increase significantly: 0.61 claims PPPM in the pre-index period versus 0.85 PPPM in the post-index period (P = 0.121), and days of therapy were 20.31 PPPM versus 30.24 PPPM, respectively (P = 0.063).
There was no significant change in the use of ER visits related to migraine (ICD-9-CM code 346.xx), tension headache (ICD-9-CM code 307.81), or headache (ICD-9-CM 784.0, also known as pain in head not otherwise specified), from 0.07 ER visits PPPM in the pre-index period to 0.10 PPPM in the post-index period (P = 0.449, Table 4 and Figure 5 ). The migraine-related and nonmigraine-related combined (all-cause) medical/hospital and pharmacy expense, including botulinum toxin, increased by 111.3%, from $651.13 PPPM in the pre-index period to $1,376.05 PPPM in the post-index period (P < 0.001, Table 4 ).
■■ Discussion
Despite the increasing number of medication options to treat and prevent migraine, many patients look to nontraditional options to find relief of refractory migraine and headache. One nontraditional option is botulinum toxin. Currently, published literature demonstrates mixed efficacy in the reduction of frequency and severity of migraine and headache symptoms with the use of botulinum toxin. [5] [6] [7] Many of these studies lack information on the impact of botulism toxin on the QOL of migraine sufferers independent of the effect on the migraine frequency. Also lacking is information about the use of acute and preventive medications, as well as migraine-related ER visits before and after the use of botulinum toxin. Our study suggests that use of botulism toxin injections in the management of migraine in a patient population that had failed many alternative therapies was associated with a reported improvement in the QOL for the majority of patients treated with botulinum toxin in a naturalistic setting.
The number of patients who were sent a survey was relatively small, but the response rate was good (63%). We attribute the high response rate primarily to the small financial remuneration. 18 (6) 9 (3) 30 (10) 21 (7) 21 (7) Work productivity and absence c 22 (7) 6 (2) 13 (4) 31 (10) 28 (9) Your recreational activities a 18 (6) 9 (3) 21 (7) 26 (9) 26 (9) Your enjoyment of life a 21 (7) 3 (1) 15 (5) 35 (12) 
Humanistic, Utilization, and Cost Outcomes Associated With the Use of Botulinum Toxin for Treatment of Refractory Migraine Headaches in a Managed Care Organization

A $5.00 bill was placed in each survey, which may have given some subjects a sense of responsibility to complete and return the survey in exchange for the money. For this health plan, in order for patients to receive coverage of botulinum toxin for migraine or headache, patients must have exhausted many other conservative treatments. Preauthorization requirements must be met prior to starting therapy, including failure of many acute and preventive medications ( Figure 6 ). Prior-authorization criteria were not verified retrospectively for each patient in the study population. However, reimbursement 
of botulinum toxin (HCPCS codes J0585 and J0587) is blocked for initial therapy for the treatment of any condition, including migraine or headache. Initial reimbursement authorization is for 6 months, after which time patient chart notes need to be reviewed prior to an extension of the prior authorization. Of note, despite patient perception of improved QOL for about 3 out of 4 respondents, cost-savings were not realized with the addition of botulinum toxin to their treatment. The 18-month follow-up period may not have been enough time for most patients to receive more than botulinum toxin injection, and a longer follow-up period may have provided more time for the neurologists and other physicians to note patient improvement and begin decreasing some of the chronic oral medications the patients were taking.
Our cost and utilization data may be compared with the retrospective analysis of administrative claims reported by Etemad et al. that found that new triptan users compared with continuous triptan users had fewer triptan unit equivalents (medians of 11 vs. 30, respectively, P < 0.05) and had less migrainerelated pharmacy expense ($506 vs. $1,505 PPPY, in 2001 dollars, P < 0.05).
1 The number of migraine ER visits per 100 patients per year for new triptan users was not significantly less than for continuous triptan users (6.15 vs. 9.43). The mean total medical and pharmacy expense for new triptan users was less than for continuous triptan users ($621 vs. $1,628 PPPY, P < 0.05). Our mean migraine-related prescription costs, prior to botulinum toxin $142 PPPM), are similar to those of Etemad et al.'s population taking preventive medications ($141 PPPM, in 2001 dollars not adjusted for inflation). However, our ER utilization and costs were more than 10-fold higher in these treatment-resistant migraine patients compared with the population of migraine patients reported by Etemad et al. Our migraine-related ER costs were $18.25 PPPM pre-index and $32.65 PPPM post-index, compared with $1.43 PPPM in the report by Etemad et al. for migraine patients receiving migraine prophylaxis drug therapy (n = 286) and $0.45 PPPM for the entire population (n = 8,488) of patients who used triptans.
Limitations
Foremost among the limitations of this study is its simple pre-to-post longitudinal design with no compari son group. Second, survey research results can be affected by small sample size and response bias. This study has a relatively small sample size (n = 54), and the respondents (63%, n = 34) were likely to be very interested in the subject of migraine syndrome. Response bias is also likely because patients who responded positively to botulinum toxin were probably more likely to return the survey.
Third, a potential limitation is that the data were not differentiated for patients who used botulinum toxin type A (Botox) versus botulinum type B (Myoblock), since the preauthorization criteria do not restrict coverage to a specific botulinum toxin. However, approximately 90% of botulinum toxin used was botulinum toxin type A (data not reported). Fourth, the dose and technique used to administer the botulinum toxin treatments likely varied between administering physicians, and these differences were not captured in this study.
Fifth, we did not assess the number of botulinum toxin treatments, the number of neurology office visits for injections, the length of time between visits, or the quality of follow-up performed by neurologists after the botulinum toxin administration. Sixth, we found that the use and cost of acute migrainerelated medication increased after botulinum toxin treatment, but we were not able to assess over-the-counter pain medications through pharmacy claims. If migraine-medication journals of these patients were assessed in addition to pharmacy claims, we could have obtained a more accurate account of when and how the medications were actually taken.
■■ Conclusion
Approximately 3 out of 4 patients who received botulinum toxin for refractory migraine after failing several acute and prophylactic treatment options self-reported improvement in disease-specific symptoms and overall QOL. However, the use of acute migrainerelated prescription medications increased after the use of botulinum toxin therapy, and hospital ER services related to migraine or headache did not decrease. Overall medical and pharmacy cost increased in the period after botulinum toxin treatment. 
